EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A cancer stem cell-directed nano-chemotherapy enhances anti-PD-L1 immunotherapy in breast cancer by inducing immunogenic cell death

Jingjing Wang, Kamel S Ahmed, Dengxuan Mao, Andrew N Shelling, Stephen M F Jamieson, George Laking, David Porter, Jing Li, Patrick Pan, Emma Nolan, Nianping Feng, Zimei Wu

Acta Biomaterialia · 2026-07 · 218 · 525-541

DOI: 10.1016/j.actbio.2026.06.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-07. Verfasst von Jingjing Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1023, New Zealand. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Immunotherapy, Immunogenic Cell Death, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Maurice Wilkins Centre for Molecular Biodiscovery, Cancer Society of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade, exemplified by anti-PD-L1 antibody (αPD-L1), has revolutionized cancer immunotherapy. Nevertheless, its therapeutic potential is constrained by the inherently low tumor immunogenicity and the persistence of cancer stem cells (CSCs), which drive immune escape and tumor recurrence. Here, a CSC-targeted, pH-sensitive liposomal nano-cocktail of doxorubicin and bufalin (PSLB/D), was demonstrated to elicit robust immunogenic cell death (ICD), thereby potentiating the efficacy of αPD-L1 in immunologically 'cold' triple-negative breast cancer (TNBC) models. The PSLB/D itself demonstrated potent synergistic tumor-inhibitory effects in both cell lines and 3-D tumor spheroids, and effectively eliminated CSCs, with 85-90% reductions in both primary and secondary sphere formation. Deep penetration and robust ICD-mediated immune response were observed in patient-derived organoids, highlighting its translational potential. The therapeutic efficacy was validated in immunocompromised MDA-MB-231 and immunocompetent 4T1 orthotopic mouse models. Notably, in immunocompetent 4T1 models, PSLB/D induced strong expression of calreticulin, leading to the recruitment of dendritic cells and cytotoxic CD8⁺ T cells. Activation of these immune cells converted the immunosuppressive 'cold' tumors into immunogenic 'hot' ones, substantially amplifying the effectiveness of αPD-L1. This chemo-immunotherapy also generated memory T cells, suggesting the potential for longer antitumor immune responses. STATEMENT OF SIGNIFICANCE: Cancer recurrence and immune evasion in triple-negative breast cancer (TNBC) are largely driven by resilient cancer stem cells (CSCs). This study introduces a pH-sensitive liposomal nano-cocktail composed of doxorubicin and a CSC inhibitor, specifically engineered to overcome the immunosuppressive tumor microenvironment. We demonstrate that this nanococktail triggers potent immunogenic cell death (ICD) in patient-derived organoids and orthotopic models, exceeding the efficacy of conventional formulations or monotherapy. By successfully converting "cold" TNBC tumors into immunologically "hot", the nano-cocktail significantly amplifies anti-PD-L1 immunotherapy outcomes. These findings offer a compelling evidence-based framework for integrating targeted nanomedicine with clinical chemo-immunotherapy protocols to prevent recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Stem CellsImmunotherapyImmunogenic Cell DeathB7-H1 AntigenTriple Negative Breast NeoplasmsFemaleHumansAnimalsCell Line, TumorMiceDoxorubicin

Stichwörter der Autor:innen

Cancer stem cellChemo-immunotherapyEndosomal escapeImmune checkpoint blockageImmunogenic cell death

Substanzen

B7-H1 AntigenDoxorubicinCD274 protein, human

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1023, New Zealand.
  • School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
  • Centre for Cancer Research, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1023, New Zealand.
  • Auckland Regional Cancer and Blood Service, Auckland City Hospital, Auckland 1023, New Zealand.
  • Centre for Cancer Research, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1023, New Zealand. Electronic address: emma.nolan@auckland.ac.nz.
  • School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: npfeng@shutcm.edu.cn.

Förderung

  • Maurice Wilkins Centre for Molecular Biodiscovery
  • Cancer Society of New Zealand

Zitieren

APA

Wang, J., Ahmed, K. S., Mao, D., N Shelling, A., M F Jamieson, S., Laking, G., Porter, D., Li, J., Pan, P., Nolan, E., Feng, N., & Wu, Z. (2026). A cancer stem cell-directed nano-chemotherapy enhances anti-PD-L1 immunotherapy in breast cancer by inducing immunogenic cell death. Acta Biomaterialia, 218, 525-541. https://doi.org/10.1016/j.actbio.2026.06.007

Vancouver

Wang J, Ahmed KS, Mao D, N Shelling A, M F Jamieson S, Laking G, et al. A cancer stem cell-directed nano-chemotherapy enhances anti-PD-L1 immunotherapy in breast cancer by inducing immunogenic cell death. Acta Biomaterialia. 2026;218:525-541. doi:10.1016/j.actbio.2026.06.007

BibTeX
@article{Wang2026,
  author = {Wang, Jingjing and Ahmed, Kamel S and Mao, Dengxuan and N Shelling, Andrew and M F Jamieson, Stephen and Laking, George and Porter, David and Li, Jing and Pan, Patrick and Nolan, Emma and Feng, Nianping and Wu, Zimei},
  title = {A cancer stem cell-directed nano-chemotherapy enhances anti-PD-L1 immunotherapy in breast cancer by inducing immunogenic cell death},
  journal = {Acta Biomaterialia},
  year = {2026},
  volume = {218},
  pages = {525--541},
  doi = {10.1016/j.actbio.2026.06.007}
}
Kostenlos starten →